| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IU1 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.6 |
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Mdivi-1 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | BRD-K09587429 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.019 | 0.6 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.6 |